Cytokinetics, Incorporated just announced positive results of their Phase IIa study of tirasemtiv (formerly CK-2017357) in people with the autoimmune neuromuscular disease, generalized myasthenia gravis. Tirasemtiv has been shown to activate skeletal muscle, as well as reduce and delay the onset of muscle fatigue. In April, the FDA granted an orphan drug designation and fast track status to tirasemtiv for the potential treatment of ALS. Cytokinetics is currently recruiting participants for their Phase IIb study of tirasemtiv in people with ALS. Cytokinetics plans to enroll around 400 people with ALS in the clinical trial.
Click here to read more.Share this: